Srdan verstovsek biography

John Robinson, PhD. Brad Barnett. Erin Schellhammer. Evan Kearns, JD. John Green. The Cogent team is driven to discover and develop novel precision medicines. Beginning with bezuclastinib, we strive to improve the lives of patients fighting rare, genetically driven diseases. Board of Directors. Peter Harwin. Chris Cain. Karen Ferrante.

Arlene M. Matthew E. Todd E. Research Leadership. Brad Fell.

Srdan verstovsek biography: Srdan Verstovsek, MD, PhD,

Francis Sullivan, PhD. Shannon Winski, PhD. Development Leadership. Ben Exter, PharmD. Mark Lohman. Dana Martin, PharmD. Lei Sun, PhD. Courtney Watson. Scientific Advisory Board. Michael Vasconcelles, MD. Sylvia Adams, MD. Scroll to Top. Andy is an accomplished executive with extensive commercial, development, and strategic leadership experience during a year career in the pharmaceutical industry, with a specific focus on oncology and hematology products.

At Array, he was responsible for leading the sales, marketing, manufacturing, and corporate strategy teams, culminating in the successful commercialization of Mektovi and Braftovi for the treatment of BRAF mutant metastatic melanoma. Prior to working at Array, Andy held management positions at both Hospira, Inc. In his spare time, Andy enjoys hiking and skiing with his wife and kids.

Srdan verstovsek biography: Dr. Srdan Verstovsek is

Evan is a team-oriented leader with more than a dozen years of experience serving as both in-house and outside counsel to biotech companies. In his spare time, Evan is usually in an ice rink or on a ball field or golf course with his wife and three children. John brings nearly 20 years of strategic finance and accounting experience to his position, nearly half of which has been in the Biotech industry for both public and private companies.

Throughout his career in biotech he has managed the strategic build out of numerous finance teams aligning people, processes and systems to the strategic goals of the organization.

Srdan verstovsek biography: Biography. Dr. Verstovsek is the

This has included transactional support, strategic plan and forecasting, cash management, SEC reporting, system implementation and operational accounting. Farid has played a key role in implementing major strategic initiatives, including more than 40 research collaborations and joint ventures, and led the company through its IPO in Farid currently serves on the board of directors of ShouTi.

Previously, he served on the board of Nimbus Therapeutics, a biotechnology company he helped found in Farid began his career in academia and was an assistant professor in the chemistry department at Rutgers University. He was a National Institutes of Health postdoctoral srdan verstovsek biography in the Department of Biochemistry and Biophysics at the University of Pennsylvania and received his doctorate degree in chemistry from Caltech.

He is an author on 70 peer reviewed publications. Levine earned his A. His laboratory has identified myeloproliferative neoplasm MPN predisposition alleles and characterized somatic genetic and epigenetic alterations in MPN and acute myeloid leukemia AML patients, which has led to new mechanism-based therapies. Inhe was elected to the American Society of Clinical Investigation and in to the Association.

Prior to joining EcoR1 inhe was an analyst for Aquilo Partners, a boutique life-science investment bank. Sinha joined Goldman Sachs in as an associate and was named managing director in and partner in Previously, he worked at The Boston Consulting Group as a management consultant. Sinha currently serves as a member of the Board of Trustees of Stanford University.

His work helping to understand the mechanism of action of Thalidomide and related drugs was critical to establishing the novel therapeutic modality known as targeted protein degradation. He is a co-founder of Civetta Therapeutics, Neomorph, Inc. Fischer completed his undergraduate training at the Universities of Hamburg and Basel and his doctoral srdan verstovsek biography at the Friedrich Miescher Institute for Biomedical Research.

Among his major contributions in this field are: the determination of the first crystal structure of a tyrosine kinase domain insulin receptor ; the first crystal structures of small-molecule inhibitors bound to a tyrosine kinase domain fibroblast growth factor receptor ; and, with Ajax co-founder Dr. Olli Silvennoinen, the crystal structure of the JAK2 pseudokinase domain.

Hubbard holds a B. Olli Silvennoinen is Director of Biocenter Finland. Silvennoinen received his M. Silvennoinen was centrally involved in the original characterization of the JAK-STAT pathway and his laboratory has continued to elucidate the regulatory mechanisms of JAK kinases in malignancies and autoimmune diseases. He has been active in facilitating research innovations in both academic settings and start-up companies.

His research interests are focused on the molecular pathogenesis of myeloproliferative neoplasms MPNs. Skoda obtained his M. He began his research career as a postdoctoral fellow at the Biozentrum of the University of Basel and later moved to the Department of Genetics at Harvard Medical School. InDr. Skoda was appointed to his current professorship in Basel and served as chair of the Department of Biomedicine until May Inhe was elected to the Swiss Academy of Medical Sciences.

What interested you and how it was all the way back, and you said when you started. Because so much new knowledge is gathered in so many new therapies are being developed. If you like a field for new drug development, we need it. When I started my career in hematology-oncology some years ago, there was not much for MPN patients that there was available at all.

Most were given some kind of form of chemotherapy or what we call supportive care therapy or palliative care. That means they were sent to the hospice soon. But imagine some years ago, there was not much to do. So that is what brought me to the field to discover and help people that were coming to see me and us at the MD Anderson Cancer Center in Houston as being here center where we did not have anything to offer to MPN patients.

So we established the center and now through team effort. Remember, this is a team effort. I am just a representative of many good people that work with me. We are really in a position to lead many studies for possible approval for patients with MPN and other conditions, not just myelofibrosis.